From Our Readers

From Our Readers

Workplace Violence

In our March 2018 issue, ASH Clinical News Associate Editor Alice Ma, MD, recounted an unnerving experience with a threatening patient in “Not What...

How would you manage a patient who meets morphologic, but not molecular, criteria for...

Here’s how readers responded to a You Make the Call question about a patient with a morphologic presentation suggestive of acute promyelocytic leukemia (APL),...

How would you treat a patient with the C282Y mutation and a family history...

Here’s how readers responded to a You Make the Call question about managing a patient with the C282Y mutation and a family history of...

What are the treatment options for a pregnant woman with chronic-phase CML?

Here’s how readers responded to a You Make the Call question about managing a pregnant patient with chronic-phase (CP) chronic myeloid leukemia (CML). Disclaimer: ASH does...

How would you manage VTE risk in a transgender patient who needs hormone replacement...

Here’s how readers responded to a You Make the Call question about venous thromboembolism (VTE) risk in a transgender patient who needs hormone replacement...

Doing No Harm Versus the Right to Bear Arms

In our December 2017 issue, “Gun Violence: A Public Health Crisis,” we spoke with experts about the complexities of treating gun control as a...

CROs: A Universal Problem

Contract research organizations (CROs), which are used by much of the pharmaceutical industry to outsource research regulatory requirements, should be the epitomes of high-quality...

How would you treat a pregnant patient with type 2A von Willebrand disease?

Here’s how readers responded to a You Make the Call question about treatment options for a pregnant patient with type 2A von Willebrand disease. Disclaimer:...

How would you treat an older patient with pancytopenia who was diagnosed with ALL?

Here’s how readers responded to a You Make the Call question about treating a patient with acute lymphocytic leukemia who is of advanced age. Disclaimer:...

How should you treat a patient with lymphoma who developed “chemo brain” after R-CHOP...

Here’s how readers responded to a You Make the Call question about neurologic toxicity following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Disclaimer: ASH does not...
Advertisement

Current Issue

May 2018, Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.